Cosmo Pharmaceuticals N.V (C43) — Capital Reinvestment Ratio
Cosmo Pharmaceuticals N.V (C43) has a Capital Reinvestment Ratio of 0.18x as of June 2022, meaning it reinvests 0% of its operating cash flow (€6.28 Million) in capital expenditures (€1.11 Million). See C43 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cosmo Pharmaceuticals N.V Capital Reinvestment Ratio (2016–2024)
This chart tracks Cosmo Pharmaceuticals N.V's Capital Reinvestment Ratio across 6 annual periods. Check Cosmo Pharmaceuticals N.V (C43) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V from 2016 to 2024. For live market cap and broader valuation context, see Cosmo Pharmaceuticals N.V market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €162.41 Million | €5.65 Million | ▼ -92.4% |
| 2023 | 0.46x | €33.62 Million | €15.31 Million | ▲ +107.0% |
| 2022 | 0.22x | €33.23 Million | €7.31 Million | ▼ -49.4% |
| 2021 | 0.44x | €12.61 Million | €5.49 Million | ▲ +37.1% |
| 2020 | 0.32x | €12.98 Million | €4.12 Million | ▼ -62.6% |
| 2016 | 0.85x | €21.69 Million | €18.43 Million | — |